Patients
NSCLC, pneumonitis, pneumonia, lung infections, interstitial pneumonia
PNEUMONITIS, METASTASIS, PNEUMONIA, INTERSTITIAL PNEUMONIA, LUNG INFECTION, NSCLC, ONCOLOGY
This retrospective study selected patients pathologically diagnosed with advanced NSCLC and treated with ICIs at our institution between January 1, 2018, and December 30, 2021. Patients were enrolled according to the following criteria: (a) All patients were pathologically diagnosed with NSCLC according to the World Health Organization histological classification; (b) patients with stage IIIB‐IV NSCLC according to the eighth edition of the tumor‐ nodal‐ metastasis staging system; (c) patients with complete clinical and imaging data for evaluation are available; (d) Eastern Cooperative Oncology Group performance status (ECOG PS): 0–2; and (e) age ≥18 years old. We excluded patients with pre‐existing radiation‐associated pneumonia or other severe interstitial pneumonia and lung infections before treatment with ICIs and patients who underwent radiotherapy after receiving ICIs and developing pneumonitis. All eligible patients were randomly divided into a training and testing set at a 7:3 ratio. This study has been approved by the Ethics Committee of our institution (No. KS(Y)21310) and was conducted following the Declaration of Helsinki (as revised in 2013).